PMID- 31871476
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2019
DP  - 2019
TI  - Effects of Deoxyschisandrin on Visceral Sensitivity of Mice with Inflammatory 
      Bowel Disease.
PG  - 2986097
LID - 10.1155/2019/2986097 [doi]
LID - 2986097
AB  - The aims of this study were to build an IBD mouse model and further to observe 
      the effects of deoxyschisandrin on IBD and visceral sensitivity and to evaluate 
      the relevance of brain-derived neurotrophic factor (BDNF) to intestinal 
      hypersensitivity of IBD mice. The results showed that deoxyschisandrin could 
      depress the contraction of isolated smooth muscle, modulate gastrointestinal 
      function, and efficiently decrease the disease activity index (DAI) of IBD mice, 
      which proved that deoxyschisandrin had antidiarrheal effects on the animals. In 
      the colorectal distention (CRD) experiment, visceral sensibility was increased in 
      the model group. However, abdominal withdrawal reflex (AWR) scores were decreased 
      after deoxyschisandrin intervention, indicating that deoxyschisandrin could 
      reduce the visceral hypersensitivity of IBD mice. Both IHC observation and 
      western blotting analysis showed that BDNF protein expression increased evidently 
      in colon of IBD mice. After the intervention of deoxyschisandrin, colon mucosa 
      BDNF protein expression in IBD mice decreased, indicating that deoxyschisandrin 
      could decrease mouse intestinal sensitivity by reducing colon mucosa BDNF 
      expression. In conclusion, deoxyschisandrin possessed antidiarrheal effects and 
      visceral hypersensitivity inhibitory effects in the mice with IBD induced by 
      TNBS, which was related to the reduction in BDNF expression in the colon.
CI  - Copyright (c) 2019 Zhili Xu et al.
FAU - Xu, Zhili
AU  - Xu Z
AUID- ORCID: 0000-0003-4764-8595
AD  - College of Pharmacy, Liaoning University of Traditional Chinese Medicine, 
      Shenyang, Liaoning 116600, China.
FAU - Zhang, Mingbo
AU  - Zhang M
AD  - College of Pharmacy, Liaoning University of Traditional Chinese Medicine, 
      Shenyang, Liaoning 116600, China.
FAU - Dou, Deqiang
AU  - Dou D
AD  - College of Pharmacy, Liaoning University of Traditional Chinese Medicine, 
      Shenyang, Liaoning 116600, China.
FAU - Kang, Tingguo
AU  - Kang T
AD  - College of Pharmacy, Liaoning University of Traditional Chinese Medicine, 
      Shenyang, Liaoning 116600, China.
FAU - Li, Feng
AU  - Li F
AUID- ORCID: 0000-0002-9700-7844
AD  - Department of Interventional Therapy, First Affiliated Hospital of Dalian Medical 
      University, Dalian, Liaoning 116001, China.
LA  - eng
PT  - Journal Article
DEP - 20191204
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC6913379
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2019/12/25 06:00
MHDA- 2019/12/25 06:01
PMCR- 2019/12/04
CRDT- 2019/12/25 06:00
PHST- 2019/08/04 00:00 [received]
PHST- 2019/10/20 00:00 [revised]
PHST- 2019/11/08 00:00 [accepted]
PHST- 2019/12/25 06:00 [entrez]
PHST- 2019/12/25 06:00 [pubmed]
PHST- 2019/12/25 06:01 [medline]
PHST- 2019/12/04 00:00 [pmc-release]
AID - 10.1155/2019/2986097 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2019 Dec 4;2019:2986097. doi: 
      10.1155/2019/2986097. eCollection 2019.